Listed

Sunshine Biopharma Inc.: Form 10-Q for the period ended Sep 30, 2013

Filed with the SEC on Nov 4, 2013 and accepted by EDGAR at Nov 4, 2013, 16:37 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development9 months2013-01-01 to 2013-09-30$23.4kus-gaap:ResearchAndDevelopmentExpense
Operating income9 months2013-01-01 to 2013-09-30−$1.3mus-gaap:OperatingIncomeLoss
Interest expense9 months2013-01-01 to 2013-09-30$6.1kus-gaap:InterestExpense
Net income9 months2013-01-01 to 2013-09-30−$1.8mus-gaap:NetIncomeLoss
Basic EPS9 months2013-01-01 to 2013-09-30−$0.03us-gaap:EarningsPerShareBasic
Operating cash flow9 months2013-01-01 to 2013-09-30−$524.7kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2013-09-30$71.0kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-09-30$71.6kus-gaap:AssetsCurrent
Total assetsAt period end2013-09-30$71.6kus-gaap:Assets
Total liabilitiesAt period end2013-09-30$23.5kus-gaap:Liabilities
Shareholders' equityAt period end2013-09-30$48.1kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001354488-13-005974. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.